Abstract
Data for the efficacy of adjuvant chemotherapy in urothelial cancer comes from prematurely closed trials with poor accrual that have not yielded definitive conclusions about benefit. Yet, the potential activity reported in these trials has been promising enough to encourage investigators to pursue assessment of this treatment. In The Lancet Oncology, Cora Sternberg and colleagues1 report the results of the EORTC 30994 trial, which compared immediate versus deferred cisplatin-based combination chemotherapy after radical cystectomy in patients with urothelial carcinoma of the bladder.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
